- Pfizer Inc (NYSE:PFE) shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid (nirmatrelvir and ritonavir tablets) in patients at standard risk for developing severe COVID-19.
- In previously reported interim analyses, the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met.
- Non-significant 70% relative risk reduction was observed in the key secondary endpoint of hospitalization or death.
- Related: Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections.
- An updated analysis from 1,153 patients showed a non-significant 51% relative risk reduction.
- A sub-group analysis of 721 vaccinated adults with at least one risk factor for progression to severe COVID-19 showed a non-significant 57% relative risk reduction in hospitalization or death.
- See Next: Read Why Pfizer Is Limiting Supply Of Paxlovid For Combination Studies: Bloomberg.
- Pfizer said it would include the new data in the company's upcoming application to the FDA seeking full approval for the drug's use in high-risk groups.
- Pfizer said it would halt enrollment in the EPIC-SR trial in standard-risk patients as the study revealed the treatment was ineffective in reducing symptoms in that group.
- Price Action: PFE shares are up 0.56% at $48.19 during the premarket session on the last check Wednesday.
- Photo via Wikimedia Commons
